Main characteristics of PID patients and schools
| . | ||
|---|---|---|
| PID patients (N = 13) | ||
| Age | Median/IQR | 13.8/13–15 |
| Sex | M/F | 8/5 |
| Level of functioning | Level 0/1/2/3 | 4/3/4/2 |
| Treatment | IgRT/SCT | 6/1 |
| PID Dx | X-linked agammaglobulinemia | 3 |
| Ataxia telangiectasia | 2 | |
| Chronic granulomatous disease | 2 | |
| STAT3-LOF hyper IgE syndrome | 1 | |
| Autoimmune lymphoproliferative syndrome | 1 | |
| SAVI | 1 | |
| Combined immunodeficiencies with associated or syndromic features | 1 | |
| Autoinflammatory disorders (non-inflammasome-related conditions) | 1 | |
| Predominantly antibody deficiencies (severe reduction in at least two serum immunoglobulin isotypes with a normal or low number of B cells, CVID phenotype) | 1 | |
| Frequency of psychology visits | Weekly/monthly/quarterly | 2/7/4 |
| Parents (N = 21) | Father/mother | 9/12 |
| Schools (N = 13) | ||
| Type of school | Public/private | 11/2 |
| Prior school coordination | Yes/no | 9/4 |
| Schools with classmate participation | Yes/no | 9/4 |
| Classmates (N = 74) | Male/female/non-binary | 34/39/1 |
| . | ||
|---|---|---|
| PID patients (N = 13) | ||
| Age | Median/IQR | 13.8/13–15 |
| Sex | M/F | 8/5 |
| Level of functioning | Level 0/1/2/3 | 4/3/4/2 |
| Treatment | IgRT/SCT | 6/1 |
| PID Dx | X-linked agammaglobulinemia | 3 |
| Ataxia telangiectasia | 2 | |
| Chronic granulomatous disease | 2 | |
| STAT3-LOF hyper IgE syndrome | 1 | |
| Autoimmune lymphoproliferative syndrome | 1 | |
| SAVI | 1 | |
| Combined immunodeficiencies with associated or syndromic features | 1 | |
| Autoinflammatory disorders (non-inflammasome-related conditions) | 1 | |
| Predominantly antibody deficiencies (severe reduction in at least two serum immunoglobulin isotypes with a normal or low number of B cells, CVID phenotype) | 1 | |
| Frequency of psychology visits | Weekly/monthly/quarterly | 2/7/4 |
| Parents (N = 21) | Father/mother | 9/12 |
| Schools (N = 13) | ||
| Type of school | Public/private | 11/2 |
| Prior school coordination | Yes/no | 9/4 |
| Schools with classmate participation | Yes/no | 9/4 |
| Classmates (N = 74) | Male/female/non-binary | 34/39/1 |
To calculate the patient’s level of functioning, we used the Eastern Cooperative Oncology Group performance status scale (19). CVID, Common variable immunodeficiency; Dx, diagnosis; IgRT, immunoglobulin replacement therapy; SAVI, STING-associated vasculopathy with onset in infancy; SCT, stem cell transplantation.